Phase 2 HS topline results maintain sonelokimab on a best-in-class trajectory
Over the weekend, MoonLake announced top-line results from the MIRA phase 2 with sonelokimab in Hidradenitis Suppurativa (HS). While more details will be disclosed in the call later today, results came in line with our base case with sonelokimab achieving a HiSCR75 of 29% (pb-adj), positioning it o
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.